CTOs on the Move

Aeroflow Healthcare

www.aeroflowinc.com

 
Live Better Today! Durable medical equipment covered by insurance delivered to your door!
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Acura Pharmaceuticals

Acura Pharmaceuticals is a Palatine, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cascade Healthcare Solutions

After beginning as a successful online company in 2009, Cascade Healthcare Solutions recently decided to open a physical store in Renton, Washington. Now we are able to meet the needs of our Local Customers, while maintaining a national online presence...

BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

CONSEJO COUNSELING & REFERRAL SERVICE

Consejo provides culturally competent behavioral health, substance abuse and domestic violence services to Latinos in King and Pierce Counties.

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.